Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.39, marking a -0.85% move from the previous day.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.
Rockwell Medical (RMTI) Soars 20.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Rockwell Medical (RMTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -32.52% in 4 Weeks
by Zacks Equity Research
Canopy Growth Corporation (CGC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -32.59% in 4 Weeks, Here's Why Canopy Growth Corporation (CGC) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Canopy Growth Corporation (CGC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Medtronic (MDT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 71.11% and 5.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 16.67% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 2.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -23.9% in 4 Weeks
by Zacks Equity Research
Canopy Growth Corporation (CGC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF
by Zacks Equity Research
Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF have been highlighted in this Investment Ideas article.
Pot Stocks Surge on SAFE Banking Act Reintroduction
by Bryan Hayes
Lawmakers are attempting to make a final push toward delivering financial services for the cannabis industry.
Humana (HUM) Rewards Shareholders With a 12.4% Dividend Hike
by Zacks Equity Research
Humana's (HUM) capital position with strong cash-generating abilities and a solid balance sheet will likely sustain its shareholder-friendly moves.
Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -169.23% and 11.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Phibro Animal Health (PAHC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 13.33% and 2.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $2.38, moving -0.42% from the previous trading session.
Wednesday Recap: Minty Fresh Breadth
by Andrew Rocco
Breadth is an important measure used by investors to determine how strong or weak a market index is beneath the surface. Tuesday, the market flashed very strong breadth - an indication that bulls may be ready to take back the baton.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $2.31, moving +1.32% from the previous trading session.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $2.33, moving +1.75% from the previous trading session.
Canopy Growth Corporation (CGC) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $2.60, moving -0.38% from the previous trading session.
Pot Stocks Get Smoked: What's Behind the Move?
by Andrew Rocco
Marijuana-related stocks reversed gains from earlier in the week as revelations emerged that a recent marijuana bill is unlikely to pass.
Canopy Growth Corporation (CGC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -55.56% and 0.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?